The FDA has accepted a BLA under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec to treat Huntington’s disease.

AbbVie has announced a licensing agreement with Beijing-based Brise Pharmaceuticals, which will see the pair work together to progress and potentially commercialise a set of early ...

MVA-BN was originally developed in collaboration with the US Government as a smallpox vaccine. Credit: Bavarian Nordic. Bavarian Nordic has secured a four-year contract from the UK Government to ...

Pelthos Therapeutics has agreed to merge with Castle Creek Biosciences to form a new biotechnology company that will focus on serious diseases affecting the skin.

Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP).

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

Astellas will continue development of DAX-044, which is expected to enter Phase I in 2027. Credit: Lightspring / Shutterstock.com. Astellas Pharma has inked a billion-dollar licensing deal with ...